Skip to main content

FDA moves signal storm warning for pharma firms (hindu)

Regulator to expedite approvals for generics to damp prices

The U.S. Food and Drug Administration’s moves on generics are a storm warning for pharma. In a bid to combat high prices, new commissioner Scott Gottlieb will expedite reviews of generic-drug applications to promote competition. The changes will batter the likes of Valeant and Cardinal Health, and cast a cloud over branded drug makers.

The FDA traditionally left questions of pricing to pharma firms, but a political uproar about gouging has prompted a rethink. Companies have jacked up the prices of branded and generic drugs needed by AIDS patients, premature infants and cancer victims, among others in some cases by 100-fold or more.

Mallinckrodt’s drug for infantile spasm, which cost about $40 a vial around the turn of the millennium, is now over $30,000. Such behaviour has crept into the $85 billion-a-year U.S. generic market.

The Government Accountability Office found about one-fifth of the generics it surveyed had at least one 100% price increase over five years.

Prices are top priority


A doctor, one-time FDA official and former partner in a venture-capital firm, Mr. Gottlieb’s industry ties forced him to temporarily recuse himself from decisions involving more than 20 companies to win Congressional confirmation. Yet he has been anything but a pharma shill since taking office, making drug prices a top priority.

His plan harnesses sunlight and competition. The FDA published a list of branded drugs without patent protection, and it will expedite the approval process for generic versions of products on this list, and for any drug that has fewer than three copies. FDA research shows that generics cost about 6% less than branded alternatives when there is only one rival. With three, the price drops by more than half.

There’s more to come. The FDA will hold hearings next month on how to prevent companies from gaming the system. Tactics such as not allowing rivals to buy drugs to prove their version is equivalent will be nixed.

The initiative will intensify pressure on the generic industry, where prices are already declining at an annual rate of about 10%. Debt-laden companies that counted on price increases, like Valeant, will be hit the hardest. And distributors Cardinal Health and AmerisourceBergen will have fewer opportunities to profit from buying drugs before price rises occur. Even big pharma won’t escape these gales. GlaxoSmithKline, for example, sells over $1 billion a year of a drug for asthma in the U.S., yet the patent expired years ago and there is no direct generic competition.

Promoting alternatives is a partial prescription for U.S. healthcare’s runaway costs.

Comments

Popular posts from this blog

Cloud seeding

Demonstrating the function of the flare rack that carries silver iodide for cloud-seeding through an aircraft. 
Water is essential for life on the earth. Precipitation from the skies is the only source for it. India and the rest of Asia are dependent on the monsoons for rains. While the South West Monsoon is the main source for India as a whole, Tamil Nadu and coastal areas of South Andhra Pradesh get the benefit of the North East Monsoon, which is just a less dependable beat on the reversal of the South West Monsoon winds.

SC asks Centre to strike a balance on Rohingya issue (.hindu)

Supreme Court orally indicates that the government should not deport Rohingya “now” as the Centre prevails over it to not record any such views in its formal order, citing “international ramifications”.

The Supreme Court on Friday came close to ordering the government not to deport the Rohingya.

It finally settled on merely observing that a balance should be struck between humanitarian concern for the community and the country's national security and economic interests.

The court was hearing a bunch of petitions, one filed by persons within the Rohingya community, against a proposed move to deport over 40,000 Rohingya refugees. A three-judge Bench, led by Chief Justice of India Dipak Misra, began by orally indicating that the government should not deport Rohingya “now”, but the government prevailed on the court to not pass any formal order, citing “international ramifications”. With this, the status quo continues even though the court gave the community liberty to approach it in …

India’s criminal wastage: over 10 million works under MGNREGA incomplete or abandoned (hindu)

In the last three and half years, the rate of work completion under the Mahatma Gandhi National Rural Employment Guarantee Act (MGNREGA) has drastically declined, leading to wastage of public money and leaving villages more prone to drought. This could also be a reason for people moving out of the programme.

At a time when more than one-third of India’s districts are reeling under a drought-like situation due to deficit rainfall, here comes another bad news. The works started under the MGNREGA—close to 80 per cent related to water conservation, irrigation and land development—are increasingly not being completed or in practice, abandoned.

Going by the data (as on October 12) in the Ministry of Rural Development’s website, which tracks progress of MGNREGA through a comprehensive MIS, 10.4 million works have not been completed since April 2014. In the last three and half years, 39.7 million works were started under the programme. Going by the stipulation under the programme, close to 7…